Welcome to our dedicated page for Regen Biopharma SEC filings (Ticker: RGBPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Regen BioPharma’s latest 10-K feels like navigating a clinical protocol—hundreds of pages on NR2F6 drug candidates, patent continuations, and cash-burn projections. If you are searching for “Regen BioPharma SEC filings explained simply” or need to trace “Regen BioPharma insider trading Form 4 transactions,” you have likely felt the complexity. That’s the problem investors face with an R&D-intensive biotech whose disclosures dive deep into pre-clinical data and preferred-share structures.
Stock Titan solves it. Our AI scans every new document the moment it hits EDGAR, turning dense language into clear takeaways—whether it’s a “Regen BioPharma quarterly earnings report 10-Q filing,” an 8-K announcing a licensing deal, or a “Regen BioPharma proxy statement executive compensation” table. Interactive dashboards surface “Regen BioPharma Form 4 insider transactions real-time,” flagging executive stock moves before the market digests them. Need the big picture? One-click summaries highlight trial milestones, funding runway, and dilution risk found inside the “Regen BioPharma annual report 10-K simplified.”
Investors use these insights to: monitor R&D spend against cash reserves, compare quarter-over-quarter trial progress, and track “Regen BioPharma executive stock transactions Form 4” around material announcements. You can also explore every “Regen BioPharma 8-K material events explained” post or dive into segment notes for autoimmune versus oncology programs. From real-time alerts to historical “Regen BioPharma earnings report filing analysis,” Stock Titan provides comprehensive coverage so you make decisions based on facts, not page counts.
Quick Capital, LLC reported beneficial ownership of 3,320,000 shares of Regen BioPharma, Inc. common stock, representing 9.9% of the outstanding class. The filing states Quick Capital has sole voting and sole dispositive power over all shares reported and identifies the filer as a Wyoming LLC with its business address in Miami, FL.
The statement is a passive Schedule 13G disclosure certifying the shares were not acquired to change or influence control of the issuer. No group affiliations, subsidiaries, or holdings on behalf of others are reported, and no shared voting or dispositive powers are disclosed.
FAQ
What is the current stock price of Regen Biopharma (RGBPP)?
What is the market cap of Regen Biopharma (RGBPP)?
